top of page

Ymmunobio Appoints Angela S. Gibbs as Chief Business Officer

Updated: Feb 9, 2023

Growing preclinical-stage biotech company adds to executive team

RIEHEN, SWITZERLAND, February 8, 2023 ─ Ymmunobio AG, a preclinical stage biotech company specializing in the development of innovative treatments for cancer patients, has appointed Angela S. Gibbs, as its Chief Business Officer (CBO). The CBO role is a new position in which Gibbs will be responsible to assist in a strategy of growth for Ymmunobio and in cultivating relationships with potential partners and investors.

Gibbs has more than 15 years of experience in Life Science, building brands, managing business development, and advancing new market opportunities. She most recently served as Global Head, Strategic Marketing for Ascom Holding AG, where she led global brand stewardship, marketing transformation, and the repositioning of a new global Healthcare Platform solution.

“The addition of Angela’s expertise provides a strong support for Ymmunobio’s visibility and our transition through growth phases,” said Ymmunobio Founder and CEO Katrin Rupalla. “We’re delighted that she has joined our team with a commitment to help us realize the full vision of our asset development strategy.”

“I’m excited to help accelerate Ymmunobio’s robust growth,” said Gibbs. “The company has a remarkable portfolio of assets that are crucial for developing effective therapies for cancer, and I’m eager to share our vision with scientific and business stakeholders and investors. The work we’ll do together will be important for foundational and relationship building.”

Angela’s career has been focused on product portfolio leadership, defining new solution concepts, and delivering new-to-world technology across Product Management, New Product Innovation, and Strategic Marketing. Prior to relocating to Switzerland in 2014, Angela was Chief Marketing Officer at Surescripts USA, where she spearheaded primary research to frame strategy, product-market fit, and new capability-building investments to support market expansion and Marketing agility. She earned a Master of Business Administration from Harvard Business School.

To learn more about Ymmunobio’s activities and research, visit the website or reach out to


Ymmunobio AG is a preclinical stage oncology biotech company focused on the development of innovative treatments for cancer patients through new classes of antibodies. Those treatments present a large market potential and broad applicability in solid tumors. Ymmunobio is making extensive progress in developing antibodies that have an influence on the immune system by reinstating its immune response to cancers or directly inhibiting cancer cell proliferation. Learn more on Ymmunobio’s website and follow on LinkedIn.

Investor Relations: Dr. Katrin Rupalla,


bottom of page